GlassScriptPhysician profile
Andre Medina Sanchez
NPI 1073143780
$1,748.99
in general payments reported to CMS, 2019-2025
19 companies · $796 in 2025
The $796 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $161 · 2024: $792 · 2025: $796.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,749.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,748.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pbg Puerto Rico LLC | $179.20 | 2023-2025 | |
| Abbvie INC. | $168.50 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $162.97 | 2023-2024 | Eliquis, Reblozyl |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $151.07 | 2025 | Lifevest |
| Medtronic, INC. | $151.02 | 2025 | Reveal Linq |
| Amgen INC. | $145.04 | 2024-2025 | Repatha |
| Novartis Pharmaceuticals Corporation | $117.58 | 2024 | |
| Merck Sharp & Dohme LLC | $91.57 | 2024 | Capvaxive, Gardasil, Gardasil 9 |
| Genzyme Corporation | $89.32 | 2024 | |
| Eli Lilly Export S.A. Puerto Rico Branch | $88.11 | 2024-2025 | Zepbound, Mounjaro |
| Bayer Healthcare Pharmaceuticals INC. | $78.09 | 2025 | |
| Lilly USA, LLC | $57.86 | 2025 | Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $57.35 | 2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $55.64 | 2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $47.84 | 2023-2024 | Farxiga, Lokelma |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $44.14 | 2023 | |
| Bayer Puerto Rico INC. | $23.41 | 2025 | Kerendia |
| Boston Scientific Corporation | $20.33 | 2025 | Watchman Flx |
| Glaxosmithkline, LLC. | $19.95 | 2024 | Arexvy, Shingrix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andre Medina Sanchez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.